Atai Life Sciences (ATAI) said Tuesday the results of a phase 2a study of Beckley Psytech's BPL-003 in patients with moderate to severe alcohol use disorder were encouraging.
The open-label study involved 12 patients, who were given a single dose of BPL-003, in combination with relapse prevention cognitive behavioral therapy, the company said.
The combination resulted in "meaningful and sustained reduction in alcohol use and heavy drinking days" in the 12-week study, it said.
BPL-003 also demonstrated a favorable safety profile, with adverse events characterized as mild or moderate, Atai said.
Beckley Psytech is partly own by Atai.
Atai shares were down more than 3% in recent trading.
Price: 1.40, Change: -0.05, Percent Change: -3.45
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。